血液miR-144-3p:抑郁症的新型诊断与治疗工具
该研究在慢性社交挫败应激(CSDS)小鼠模型及MDD患者中探索循环血miRNA作为重性抑郁障碍(MDD)诊断与治疗生物标志物的潜力。研究发现应激易感小鼠与应激抵抗小鼠在潜伏期后血液miRNA特征存在显著差异,氯胺酮在行为应答小鼠中比丙咪嗪更有效地恢复基线miRNA表达水平。红细胞特异性miR-144-3p被确定为辅助抑郁诊断和预测氯胺酮治疗反应的候选生物标志物,且全身性敲低miR-144-3p足以减轻应激易感小鼠的抑郁相关表型。
要点
- 应激易感与应激抵抗小鼠在潜伏期后血液miRNA特征存在显著差异,应激暴露后即刻未见差异。
- 氯胺酮比丙咪嗪更有效地恢复基线miRNA表达水平,但仅在行为应答小鼠中如此。
- 全身性敲低miR-144-3p可减轻应激易感小鼠的抑郁相关表型并减弱转录应激特征。
核心结论
- miR-144-3p被确定为辅助MDD诊断和预测氯胺酮治疗反应的候选生物标志物,并作为抗抑郁治疗的新靶点。
研究设计与样本
- 研究对暴露于慢性社交挫败应激(CSDS)前后的小鼠循环血miRNA表达水平进行谱分析,并比较重复丙咪嗪或单次氯胺酮治疗后的变化。
- 研究在应激易感小鼠和MDD患者中评估miR-144-3p作为诊断和治疗反应生物标志物的潜力。
- 研究通过皮下注射特异性antagomir对应激易感小鼠进行miR-144-3p全身性敲低,并对敲低后血液进行RNA测序分析。
主要发现
- 应激抵抗与应激易感小鼠在潜伏期后血液miRNA特征存在显著差异,但应激暴露后即刻未见差异。
- 氯胺酮比丙咪嗪更有效地恢复基线miRNA表达水平,但仅在行为应答小鼠中如此。
- 全身性敲低miR-144-3p足以减轻应激易感小鼠的抑郁相关表型,且RNA测序显示转录应激特征减弱。
临床怎么用
- miR-144-3p可作为辅助MDD诊断和预测氯胺酮治疗反应的候选生物标志物。
- 系统性敲低miR-144-3p通过皮下注射特异性antagomir实现,可减轻应激易感小鼠的抑郁相关表型。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depressive disorder (MDD) is the leading cause of disability worldwide. There is an urgent need for objective biomarkers to diagnose this highly heterogeneous syndrome, assign treatment, and evaluate treatment response and prognosis. MicroRNAs (miRNAs) are short non-coding RNAs, which are detected in body fluids that have emerged as potential biomarkers of many disease conditions. The present study explored the potential use of miRNAs as biomarkers for MDD and its treatment. We profiled the expression levels of circulating blood miRNAs from mice that were collected before and after exposure to chronic social defeat stress (CSDS), an extensively validated mouse model used to study depression, as well as after either repeated imipramine or single-dose ketamine treatment. We observed robust differences in blood miRNA signatures between stress-resilient and stress-susceptible mice after an incubation period, but not immediately after exposure to the stress. Furthermore, ketamine treatment was more effective than imipramine at re-establishing baseline miRNA expression levels, but only in mice that responded behaviorally to the drug. We identified the red blood cell-specific miR-144-3p as a candidate biomarker to aid depression diagnosis and predict ketamine treatment response in stress-susceptible mice and MDD patients. Lastly, we demonstrate that systemic knockdown of miR-144-3p, via subcutaneous administration of a specific antagomir, is sufficient to reduce the depression-related phenotype in stress-susceptible mice. RNA-sequencing analysis of blood after such miR-144-3p knockdown revealed a blunted transcriptional stress signature as well. These findings identify miR-144-3p as a novel target for diagnosis of MDD as well as for antidepressant treatment, and enhance our understanding of epigenetic processes associated with depression.
引用
- van der Zee YY, Eijssen LMT, Mews P, et al. Blood miR-144-3p: a novel diagnostic and therapeutic tool for depression. Mol Psychiatry. 2022. PMID: 35902629. doi:10.1038/s41380-022-01712-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。